CD44 and experimental autoimmune encephalomyelitis: Studies on therapeutical aspects are currently under investigation that include the inhibition of enzymes that cleave CD44 (306) and CD44 vaccination (307), which provides partial resistance to experimental autoimmune encephalomyelitis (307).